FDA Limits Long-Acting Asthma Inhalers
The long-acting asthma drugs Serevent and Foradil should
never be used alone, the FDA has ruled.
The FDA also moved to limit use of the combination drugs Advair and
Symbicort by asthma patients. All of the drugs contain a class of drugs called
long-acting beta agonists (LABAs), which can provoke a sudden, fatal asthma
attack.
Although this deadly side effect is most common in children, adults with
asthma are also included in the FDA warning. Patients who use LABAs for COPD
(chronic obstructive pulmonary disease) are not included in the new
warning.
The FDA action:
- Warns patients not to use LABAs by themselves, but always to combine them
with other asthma-control medications. - Warns asthma patients who must use LABAs to use them for the shortest
possible time. - Limits LABA use to patients whose asthma cannot be controlled with other
drugs. - Limits use of Advair and Symbicort. Although these products do contain
asthma-control drugs, asthma patients should use these LABA-containing drugs
for the briefest time possible. - Compels LABA products to carry the FDA warning on their labels.
- Requires LABA makers to perform additional studies of the drugs'
safety. - Warns that LABA drugs do not relieve sudden-onset asthma attacks.
- Establishes a new risk management program for patients who must use
LABAs.
"The risks of hospitalization and poor outcomes are of particular concern
for children; parents need to know that their child with asthma should not be
on a LABA alone," Dianne Murphy, MD, FDA director of pediatric therapeutics,
says in a news release.
The FDA has not banned the use of single-agent LABA drugs because not all
asthma control medications can be combined with these inhaled medications.
The FDA action comes in the wake of the
December 2008 recommendation by an outside advisory panel to stop the use
of Serevent and Foradil as standalone treatments.
By Daniel DeNoon
Reviewed by Louise Chang
©2005-2010 WebMD, LLC. All rights reserved